Our data demonstrate that NB cells with a mutated p53 (CHLA90 and BE(2)‐C) are resistant to the MDM2 inhibitor CGM097, relative to wild‐type p53 cell lines (SMS‐KCNR and SH‐SY5Y), (Figure 2). The gene discussed is TP53; the disease is neuroblastoma.